IPP Bureau
Akums surges in Q3 FY26 with 15% revenue jump, bags key EU & UK nods
By IPP Bureau - February 14, 2026
Operational leverage kicked in during the quarter, with adjusted EBITDA rising 21% year-on-year to Rs 147 crore
FDA nod to Acrotech's new eczema treatment
By IPP Bureau - February 14, 2026
ADQUEY’s approval opens the door to a new alternative for millions of Americans struggling with atopic dermatitis
Fortis Healthcare posts strong Q3 FY26 growth; revenues up 17.5% YoY
By IPP Bureau - February 14, 2026
The company’s consolidated revenues rose 17.5% year-on-year to Rs. 2,265 crore
FDA refuses to file Moderna’s seasonal flu vaccine application, citing comparator issue
By IPP Bureau - February 14, 2026
The FDA’s Center for Biologics Evaluation and Research (CBER) cited Moderna’s choice of a licensed standard-dose flu vaccine as the comparator in its Phase 3 trial, saying it “does not reflect the best-available standard of care.”
Citius Oncology expands LYMPHIR access across Europe via exclusive Uniphar deal
By IPP Bureau - February 14, 2026
Under the deal, Uniphar will serve as LYMPHIR’s exclusive distribution partner across designated Western and Eastern European territories
Precision BioSciences cleared by FDA to launch groundbreaking Duchenne gene editing trial
By IPP Bureau - February 14, 2026
PBGENE-DMD is designed to permanently correct mutations in the dystrophin gene between exons 45 and 55, the “hot-spot” region affecting roughly 60% of DMD patients
BioAsia 2026 positions Telangana as a global TechBio powerhouse
By IPP Bureau - February 14, 2026
BioAsia 2026 represents a decisive shift toward execution, scale, and global competitiveness, reflecting the rapid evolution of the life sciences ecosystem
Zota Health Care expands Davaindia network to 2,502 stores nationwide
By IPP Bureau - February 13, 2026
The surge has been driven largely by COCO stores, with 755 COCO and 165 FOFO outlets added this fiscal year
OneSource bags SFDA nod for generic Ozempic in Saudi Arabia
By IPP Bureau - February 13, 2026
IOL Chemicals posts robust Q3 & 9M FY26 results, PBT up 39% YoY
By IPP Bureau - February 13, 2026
Chemicals delivered improved efficiency and optimal capacity utilization, with EBIT rising 37% YoY
Merck’s KEYTRUDA bags FDA nod for platinum-resistant ovarian cancer
By IPP Bureau - February 13, 2026
KEYTRUDA QLEX is contraindicated in patients with known hypersensitivity to its components
Merck KGaA’s Belen Garijo to become CEO of Sanofi
By IPP Bureau - February 13, 2026
Garijo will be the first woman to lead Sanofi in its history
DFE Pharma launches EcoLact 2030 to deliver verified CO2 cuts across pharma supply chains
By IPP Bureau - February 13, 2026
The program provides pharmaceutical manufacturers with auditable, primary emissions data and verified proof of a 30% CO? reduction across DFE Pharma’s lactose portfolio
Biocon posts strong Q3FY26 growth, boosted by biosimilars & generics
By IPP Bureau - February 13, 2026
Profit before tax jumped 64% to Rs. 226 crore, while the company maintained robust investment in innovation with net R&D spend of Rs. 249 crore
Supriya Lifescience delivers robust Q3 FY26 performance with 11% YoY revenue growth
By IPP Bureau - February 13, 2026
The Profit After Tax (PAT) for Q3 FY26 was Rs 49.68 crore, compared to Rs 46.78 crore in Q3 FY25
